A device can’t solve asthma by itself—but it can change what clinicians choose to trust. That’s why I find the rollout of the NObreath® fractional exhaled nitric oxide (FeNO) approach at ATS 2026 such an interesting cultural moment, not just a product update. Personally, I think this kind of breath-analysis technology is less about “new gadgets” and more about a deeper shift: medicine trying to replace guesswork with measurable signals in real time.
At the ATS International Conference in Orlando (May 15–20), Bedfont®—with its U.S. distributor coVita™—is showcasing the NObreath® at booth 1236. They’re positioning FeNO testing as a non-invasive way to get objective insight into airway inflammation, which matters because asthma is rarely uniform: the same wheeze can come from different biological drivers. In my opinion, the biggest question isn’t whether FeNO can detect inflammation—it’s whether clinicians, health systems, and patients will actually build their decisions around that information.
Breathing as data: the promise and the temptation
FeNO measurement turns something ordinary—exhaled air—into a biomarker. That’s genuinely useful, and what makes this particularly fascinating is how it reframes asthma from symptoms-first to physiology-first. Personally, I think this is the direction healthcare has been circling for years: if we can measure the “why,” we stop treating the “what.”
But I also want to be careful. What many people don’t realize is that biomarkers can become a new kind of shorthand that carries its own risks. In the real world, FeNO levels can be influenced by factors like adherence, inhaled steroid use, allergies, and timing. So the temptation is to treat FeNO like a single scoreboard, when what it really offers is one lens on a complex condition.
From my perspective, the real win is not “FeNO as truth,” but “FeNO as navigation.” Clinicians can use it to support inflammation-guided management—potentially reducing the guesswork behind stepping up, stepping down, or confirming whether symptoms match expected airway inflammation. Still, the broader trend I see here is how quickly health systems adopt metrics when they’re convenient, even before everyone agrees on interpretation.
Non-invasive isn’t the same as non-problematic
Non-invasive tools sound like a clear improvement: fewer barriers, more frequent testing, less patient discomfort. Personally, I think that matters because asthma care often breaks down at the moments when it’s hardest to stay consistent—when people are busy, stressed, or feel better and stop thinking about the underlying inflammation.
However, what this raises is a deeper question: if you make testing easy, do you also make over-testing easier? In my opinion, healthcare loves “low-friction” interventions because they scale. Yet scaling means the system can start generating data faster than it can learn from data.
One detail I find especially interesting is how FeNO fits into a larger narrative of “today’s science meets tomorrow’s care.” That line sounds marketing-friendly, but it points to a real tension: objective measurement can empower patients and clinicians, but it can also create a new anxiety loop—numbers that people feel they must “manage.” If patients come to see FeNO results as a personal grade, then a biomarker designed to support care could unintentionally undermine confidence.
The ATS spotlight: why conferences matter
ATS brings together more than 15,000 experts across pulmonary, critical care, and sleep medicine, and companies like Bedfont® use that platform to validate and accelerate adoption. Personally, I think conferences are where technology stops being a lab idea and starts becoming a clinical conversation.
But conferences are also where narratives get shaped. What many people don’t realize is that the same dataset can be framed as “revolutionary” or “incrementally helpful,” depending on who’s speaking and what they want to standardize. So when Bedfont® emphasizes NObreath® as improving asthma management for over 15 years, I interpret that as more than longevity; it’s an attempt to anchor credibility.
From my perspective, the key is whether the field treats FeNO testing as part of a thoughtful algorithm or as a standalone solution. If ATS sessions and Innovation Hubs turn into consensus-building—where clinicians compare outcomes, discuss thresholds, and define use-cases—then FeNO can become a practical tool rather than a buzzword.
Expertise and authority: the role of advisory voices
Bedfont® also highlights involvement from a respiratory expert, Carol Stonham MBE, tied to children and young people asthma leadership. Personally, I think elevating clinical advisory expertise is not just “nice to have”—it signals who is accountable for interpretation and implementation.
Here’s the commentary layer I can’t ignore: in healthcare, new measurement tools succeed when they’re wrapped in credible clinical guidance. People don’t want to buy into data; they want to know what to do with it. In my opinion, advisory figures help bridge that gap by connecting the device conversation to day-to-day practice.
At the same time, I’m skeptical of how often “expert endorsement” substitutes for rigorous, transparent evidence translation. This is where the field often misunderstands adoption: it treats clinical authority as proof of universality. In reality, effectiveness varies by population, care setting, and clinician training. For children and young people with asthma, for example, the practical workflow—who tests, how often, and how results guide treatment—can matter as much as the biomarker itself.
The bigger trend: objective inflammation and personalized-ish care
FeNO-guided approaches sit inside a broader shift toward precision medicine—but with a caveat. Personally, I think asthma isn’t going to become fully personalized in the way headlines sometimes promise. What we can reasonably build is “personalized enough”: strategies that adjust treatment based on measurable signals rather than symptoms alone.
What this really suggests is that clinicians may increasingly rely on objective markers to reduce variability caused by subjective reports. Symptoms are real, but they’re noisy. Biomarkers can help separate “I feel unwell” from “my airway inflammation is active right now,” which changes how clinicians think about escalation.
From my perspective, the hidden implication is economic and operational too. If testing becomes standardized, it can alter prescribing patterns, follow-up frequency, and even how payers view asthma management. That can be positive—less overtreatment, fewer avoidable exacerbations. But it can also create pressure to test routinely, even when it’s not clinically necessary.
Where I think the debate will go next
If you take a step back and think about it, the future argument around FeNO won’t be “does inflammation exist?” It will be “when does measurement change outcomes for specific groups?”
I expect debates to cluster around:
- When FeNO should be ordered (at diagnosis, during control assessment, after flares)
- How clinicians should act on results (adjusting inhaled corticosteroids, confirming adherence)
- How to interpret readings alongside allergy burden, infection risk, and medication timing
Personally, I think the field will also struggle with equity questions. Who gets easy access to non-invasive biomarker testing? Who pays for it? If a tool improves care in well-resourced clinics but remains unavailable elsewhere, then “objective measurement” could widen gaps rather than close them.
My takeaway: measurement is a tool, not a worldview
NObreath® at ATS 2026 represents a familiar story in modern medicine: we’re pushing toward more measurable, more standardized, more scalable care. Personally, I think that instinct is good—especially for a disease like asthma where day-to-day variability can derail decision-making.
Still, I want to end with a caution. What this really suggests is that biomarker adoption is as much about behavior and trust as it is about physiology. If clinicians treat FeNO as a guide, explain its limitations to patients, and build it into sensible decision pathways, then it can genuinely improve asthma management. If instead it becomes a single number everyone chases, we’ll replace one kind of uncertainty with another.
If you’d like, I can tailor this into a more explicitly argumentative op-ed (stronger thesis and sharper antagonists) or a more neutral “editorial analysis” style for a healthcare audience.
